drugset / Trial / NCT00920972

Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

NCT00920972

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The hypothesis for this study is that a preparative regimen that maximizes host immunosuppression without myeloablation will be well tolerated and sufficient for engraftment of donor hematopoietic cells. It is also to determine major toxicities from these conditioning regimens, within the first 100 days after transplantation.

Timeline

Start
2001-12
Primary completion
2026-12
Completion
2031-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Abatacept Other / unclassified 10 mg/kg Intravenous
Subject Methotrexate Small molecule 7.5 mg/m2 Intravenous
Subject Thiotepa Other / unclassified 8 mg/kg Intravenous
Background Alemtuzumab Monoclonal antibody Intravenous
Background Cyclosporine Peptide
Background Fludarabine Small molecule 30 mg/m2 Intravenous
Background Hydroxyurea Other / unclassified 30 mg/kg Oral
Background MMF Unknown
Background Melphalan Small molecule 140 mg/m2 Intravenous
Background Tacrolimus Small molecule